Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17807890 | 0.95 | THRB (0.36) | THRBLMNA | |
| SCHEMBL854693 | 0.89 | THRB (0.44) | THRBLMNA | |
| SCHEMBL3985906 | 0.84 | THRB (0.36) | THRBLMNA | |
| SCHEMBL322218 | 0.83 | — | — | |
| SCHEMBL2921585 | 0.80 | — | — | |
| SCHEMBL277640 | 0.80 | THRB (0.42) | THRBLMNA | |
| SCHEMBL314741 | 0.78 | THRB (0.32) | THRBLMNA | |
| Ammonia Solution, Strong SCHEMBL29215255 | 0.78 | — | — | |
| SCHEMBL11760550 | 0.78 | THRB (0.40) | THRBLMNA | |
| SCHEMBL5694826 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263586-B2 | OXO bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263586-B2 | OXO bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263586-B2 | OXO bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-09 | — | — | US | disclosed |
| WO-2008143856-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227848-A1 | OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | THRB 569/4885LMNA 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.